Published on 12/17/2009 in the Prospect News PIPE Daily.
New Issue: Neurocrine Biosciences arranges $10 million private placement of shares
By Devika Patel
Knoxville, Tenn., Dec. 17 - Neurocrine Biosciences, Inc. said it plans a $10 million private placement of stock.
The company will sell 4,784,689 common shares at $2.09 apiece.
Settlement is expected on Dec. 22.
Neurocrine is a San Diego-based product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders.
| Issuer: | Neurocrine Biosciences, Inc.
|
| Issue: | Common stock
|
| Amount: | $10 million
|
| Shares: | 4,784,689
|
| Price: | $2.09
|
| Warrants: | No
|
| Pricing date: | Dec. 17
|
| Settlement date: | Dec. 22
|
| Stock symbol: | Nasdaq: NBIX
|
| Stock price: | $2.27 at close Dec. 16
|
| Market capitalization: | $86.7 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
